Pharmacists in Vivian, LA Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Haley Bradford, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 929 S Pine St, Vivian, LA 71082 Phone: 318-375-4510 |
 Stevie Joe Roberson, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 929 S Pine St, Vivian, LA 71082 Phone: 318-375-4810 |
Lilian Ibe Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 929 S Pine St, Vivian, LA 71082 Phone: 318-375-4510 |
Dr. Savannah Rowland, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 929 S Pine St, Vivian, LA 71082 Phone: 318-375-4510 Fax: 318-375-5928 |
News Archive
Beike Biotechnology awarded ISO9001 certification for implementation of comprehensive QMS
Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, has been awarded ISO9001 certification by the International Organization for Standardization ("ISO"). This internationally recognized designation signifies Beike has established a Quality Management System (QMS) that complies with ISO9001 standards.
Iksuda Therapeutics closes $47 million financing round
Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda's lead ADC assets and expansion of its payload and conjugation platform technologies.
Two world-renowned scientists receive Poland-U.S. Science Award
World-renowned scientists - Prof. Mariusz Jaskólski of Adam Mickiewicz University in Poznań, Poland, and Dr. Alexander Wlodawer of the National Cancer Institute, USA - are the first winners of the Poland-U.S. Science Award granted jointly by the Foundation for Polish Science and the American Association for the Advancement of Science, the world's largest scientific association.
Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
› Verified 8 days ago